VivoSeq
Other

Pomalidomide

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Pomalidomide is an early-stage landscape with 0 programs across 2 companies. The most active players are Bristol-Myers Squibb, Jiangsu Simcere Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalJiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Recruiting3 · 21%
Unknown status2 · 14%
Withdrawn1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05390749·50 enrolled
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Recruiting·SSun Yat-sen University·Phase 1/2·NCT06855823·33 enrolled
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
Recruiting·UUniversity of Aarhus·Phase 1/2·NCT06660498·32 enrolled
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Active, not recruiting·CCanadian Myeloma Research Group·Phase 1/2·NCT03715478·120 enrolled
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01707407·32 enrolled
CC-4047 (Pomalidomide) for Graft vs. Host Disease
Completed·WWashington University School of Medicine·Phase 2·NCT00770757·13 enrolled
A Pilot Bioequivalence Study of Pomalidomide
Completed·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT03424928·12 enrolled
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT05555329·12 enrolled
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01835561·32 enrolled
Pomalidomide for the Treatment of Bleeding in HHT
Completed·TThe Cleveland Clinic·Phase 2·NCT03910244·145 enrolled
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01474330·33 enrolled
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
Withdrawn·—·Phase 2·NCT04584307
Study of Pomalidomide in Anal Cancer Precursors
Unknown status·KKirby Institute·Phase 2·NCT03113942·26 enrolled
A Pilot Bioequivalence Study of Pomalidomide
Unknown status·MMegalabs·Phase 1·NCT06058689·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)